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Abstract
Objective: Insulinomas are rare pancreatic neoplasms, which can usually be cured 
by surgery. As the diagnostic delay is often long and the prolonged hyperinsulinemia 
may have long-term effects on health and the quality of life, we studied the long-term 
health-related quality of life (HRQoL) in insulinoma patients.
Design, patients and measurements: The HRQoL of adults diagnosed with an insu-
linoma in Finland in 1980-2010 was studied with the 15D instrument, and the results 
were compared to those of an age- and gender-matched sample of the general popu-
lation. The minimum clinically important difference in the total 15D score has been 
defined as ±0.015. The clinical characteristics, details of insulinoma diagnosis and 
treatment, and the current health status of the subjects were examined to specify 
the possible determinants of long-term HRQoL.
Results: Thirty-eight insulinoma patients participated in the HRQoL survey (response 
rate 75%). All had undergone surgery with a curative aim, a median of 13 (min 7, 
max 34) years before the survey. The insulinoma patients had a clinically importantly 
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1  | INTRODUC TION
Insulinomas are the most common functioning endocrine neoplasms 
of the pancreas, with an estimated incidence of 1-3 per million per 
year. Over 90% of insulinomas are benign, and a vast majority of 
them are completely cured by surgery.1-3 Patients with a malignant 
insulinoma have a median survival of less than 2 years.2 Despite 
the improved diagnostic options, the diagnostic delay has remained 
long,4 and little is known about the long-term prognosis of patients 
with an insulinoma.
Studies on the health-related quality of life (HRQoL) of patients 
with gastroenteropancreatic neuroendocrine neoplasms or tumours 
(GEP-NENs, GEP-NETs) are scarce. In the existing studies, the meth-
ods and the quality of processing and reporting the HRQoL data 
vary.5 According to a recent review, despite the generally good 
HRQoL, patients with metastatic well-differentiated GEP-NETs 
have specific psychological and physical complaints.6 Impairments in 
multiple domains of HRQoL, such as emotional, role and social func-
tioning, as well as impaired excretion have been reported in GEP-
NET patients, compared to the general population.5,7-9 The HRQoL 
of insulinoma patients has not been studied before. The aim of this 
study was to evaluate the long-term HRQoL in a nationwide Finnish 
insulinoma cohort,4 and to investigate the factors determining the 
HRQoL of patients with a previously treated insulinoma.
2  | SUBJEC TS AND METHODS
2.1 | Study populations and protocol
In our previous retrospective study on insulinoma, we described 
the incidence, clinical picture, diagnostics and treatment of all adult 
Finnish patients diagnosed with an insulinoma in 1980-2010.4 The 
research register includes data on the clinical picture, laboratory 
findings, imaging, pathology, surgical and medical treatment, and the 
follow-up of the patients with an insulinoma. The decisions on the 
treatment and follow-up of insulinoma patients were made by a mul-
tidisciplinary expert team in one of the five University Hospitals in 
Finland. After curative resection of a sporadic insulinoma, usually no 
long-term follow-up investigations were organized, whereas patients 
with a syndromic, advanced or unresectable insulinoma were actively 
followed up at the University Hospital, usually every 3 to 12 months. 
Postoperative dietetic consultation was offered to patients with sec-
ondary diabetes and/or exocrine pancreatic insufficiency.
In the present study, the HRQoL of the Finnish insulinoma cohort 
was assessed with a self-administered 15D instrument, as well as a 
questionnaire on current health and medication. The questionnaires 
were sent by mail to all living insulinoma patients of the cohort in 
September 2017. A second letter was sent to all nonrespondents in 
October 2017. Address information of the study population was ob-
tained from the Population Register Centre. Each participant of the 
study gave written informed consent and a permission to combine 
the information received from the questionnaires with the data in 
the previously created register. Participation was voluntary, free of 
charge and uncompensated.
The results obtained from the participants with the 15D instru-
ment were compared to those of an age- and gender-matched sam-
ple of the general population from the National Health 2011 Health 
Examination survey (controls, n = 4692).10 After obtaining the ques-
tionnaires from the participants, the Finnish insulinoma cohort was 
divided into the groups of participants, nonparticipants and those 
deceased before the survey, for demographic and insulinoma-spe-
cific descriptions. The regional Ethics Committee of the Tampere 
University Hospital catchment area and the Finnish Institute for 
Health and Welfare reviewed and approved the study protocol. 
Research data are not shared for ethical reasons, in order to protect 
the anonymity of the patients with a rare endocrine disease.
2.2 | HRQoL and health questionnaires
2.2.1 | The 15D instrument
The 15D instrument is a generic, validated instrument for measur-
ing self-reported HRQoL among adults.11 It can be used both as a 
profile and a single index instrument and consists of 15 dimensions 
and statistically significantly better mean 15D score compared with the controls 
(0.930 ± 0.072 vs 0.903 ± 0.039, P = .046) and were significantly better off regarding 
mobility, usual activities and eating. Among the insulinoma patients, younger age at 
the time of survey, higher level of education and smaller number of chronic diseases 
were associated with better overall HRQoL.
Conclusions: In the long term, the overall HRQoL of insulinoma patients is slightly 
better than that of the general population.
K E Y W O R D S
hyperinsulinism, hypoglycaemia, insulin, insulinoma, neuroendocrine tumors, pancreas, quality 
of life
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(mobility/moving, vision/seeing, hearing, breathing, sleeping, eating, 
speech, excretion, usual activities, mental function, discomfort and 
symptoms, depression, distress, vitality and sexual activity), each di-
vided into five grades of severity. For each dimension, the patient 
chooses the level best describing his or her present health status. To 
create the 15D profile, within-dimension level values are calculated 
from the questionnaire on a scale of 0-1, a higher score reflecting 
better HRQoL on each dimension. The single index 15D score, rep-
resenting the overall HRQoL, is generated from the dimension level 
values using a set of population-based preference or utility weights, 
the maximum 15D score being 1 (no problems on any dimension) and 
minimum score 0 (equivalent to being dead). The 15D instrument has 
a high discriminatory power and responsiveness to change.12,13 The 
minimum important difference in the 15D score in a cross-sectional 
setting has been estimated to be ±0.015.14
2.2.2 | Health questionnaire
In addition to the 15D instrument, the current state of health of 
the insulinoma patients was assessed by a health questionnaire. 
The questionnaire included 14 multiple choice questions concern-
ing demographic characteristics, self-assessed health, follow-up for 
the insulinoma, glucose metabolism and any chronic diseases the pa-
tient has been diagnosed with (Appendix S1: Health Questionnaire). 
Thirteen of the questions were adapted or modified from question-
naire 115 in the National FINRISK 2012 study.16,17 The participants 
were also asked about their current height and weight, and their reg-
ular medications. The information obtained from the questionnaires 
was combined with the clinical data of the insulinoma register,4 to 
evaluate factors associated with the HRQoL of insulinoma patients.
2.3 | Statistical analysis
The statistical analysis was conducted with IBM SPSS Statistics for 
Windows, Versions 23.0, and 25.0 (IBM Corp). The data are pre-
sented as mean ± standard deviation for 15D scores, median (mini-
mum–maximum) for other numerical variables and number (%) for 
categorical variables. The characteristics of the participants, the 
nonparticipants (alive at the time of mailing the questionnaires) and 
the deceased patients were compared, using the Mann-Whitney U 
test for numerical variables and the Fisher exact test for categorical 
variables. Body mass indexes (BMI) were calculated, and the weight 
and BMI at the time of the HRQoL survey were compared with those 
at clinical insulinoma diagnosis, using the Wilcoxon signed rank test. 
The mean 15D scores and the 15D profiles between the patients and 
the controls were compared with the independent samples t test. 
The mean difference in the total 15D score between the patients 
and the controls was calculated and compared to the minimum clini-
cally important difference, previously defined as ± 0.015.14 Because 
of the non-normal distribution of the 15D variables, the analyses 
were repeated with the Mann-Whitney U test.
To examine the factors associated with the HRQoL in insulinoma 
patients, correlations between demographic and clinical character-
istics (acquired from medical reports and the Health Questionnaire) 
and the 15D scores were analysed. Spearman correlation coeffi-
cients were calculated for numerical variables. For binary variables, 
differences in the 15D scores were analysed with the Mann-Whitney 
U test. Differences in the 15D scores between different surgical 
methods were analysed with the Kruskal-Wallis test. A two-sided P 
value of <.05 was considered statistically significant.
3  | RESULTS
Of the 51 insulinoma cohort patients alive at time of the HRQoL survey, 
38 returned the questionnaires (response rate 75%). The patient char-
acteristics are summarized in Table 1. All the 38 patients participating 
in the HRQoL study had undergone insulinoma surgery with a curative 
aim, a median of 13 (7–34) years before the HRQoL survey. The surgical 
methods included 16 (42%) tumour enucleations, 16 (42%) partial pan-
creatic resections and 6 (16%) pancreaticoduodenectomies. During the 
study period, only one laparoscopic operation of insulinoma was per-
formed (data missing for two patients). In 36 of the participants, the in-
sulinoma was regarded as benign, and completely cured by surgery. In 
one participant, the insulinoma was associated with MEN1 syndrome, 
but other hereditary tumour syndromes were not diagnosed in any of 
the participants. Malignant, metastatic insulinomas were detected in 
two patients. The patients were followed up at the University Hospital 
for a median of 2 (0-374) months after the surgery, and after that the 
follow-up was either discontinued or transferred to primary or second-
ary health care. In the majority (76%) of the participants, the follow-up 
due to insulinoma had ended by the time of the survey (Table 2).
The demographic and clinical characteristics of the participants, 
nonparticipants and those deceased before the survey are shown in 
Table 1. There were no significant differences in any of these charac-
teristics between the participants and the nonparticipants. Among 
the patients deceased before the survey (n = 28), metastatic disease 
was significantly more common compared to the participants and 
nonparticipants (25% vs 5% and 0%, respectively; P = .026) and sur-
gery with a curative aim was less common (71% vs 100% and 100%, 
respectively, P = .001).
In the health questionnaire, 74% of the study participants reported 
that their health was very good or quite good, 24% average, 3% quite 
bad and none very bad. The median weight 70 (48-147) kg and BMI 25 
(19-51) kg/m2 at the time of the survey were significantly lower than 
the weight 77 (55-125) kg and BMI 26 (21-39) kg/m2 at the time of 
insulinoma diagnosis, P = .011 and .014, respectively. Twenty-seven 
(71%) respondents reported having at least one chronic disease, of 
which hypertension was the most common one, with a prevalence of 
47% (Table 2). There was no significant difference between males and 
females in the prevalence of any chronic disease. In women, however, 
the overall number of chronic diseases [2 (0-7) vs 0 (0-3), P = .031] and 
the number of medications in regular use [2 (0-18) vs 0 (0-5), P = .011] 
were significantly higher than in men. One participant (3%) was using 
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combination therapy with metformin and rapid-acting insulin for a sus-
pected secondary diabetes. None of the participants had insulin-de-
pendent diabetes requiring multiple daily injections. Three participants 
(8%) reported daily use of pancreatic enzyme supplementation, most 
probably for postoperative exocrine pancreatic insufficiency.
3.1 | HRQoL in insulinoma patients compared 
with the general population
The patients with a previously treated insulinoma had a higher mean 
15D score compared with the age- and gender-matched sample of 
the general population (0.930 ± 0.072 vs 0.903 ± 0.039, P = .046, 
Figure 1). The mean 15D difference (0.027) exceeded the limit of 
0.015 for a minimum clinically important difference,14 indicating a 
slightly better HRQoL of the insulinoma patients. Of the individual 
dimensions, mobility (0.977 ± 0.078 vs 0.911 ± 0.072, P < .001), 
usual activities (0.963 ± 0.096 vs 0.899 ± 0.077, P = .002) and eat-
ing (1.000 ± 0.000 vs 0.994 ± 0.010, P = .001) showed a statisti-
cally significant difference between the groups, indicating better 
self-reported quality of life among the insulinoma patients, com-
pared to the age- and gender-matched control group. Six patients 
(16%) reported full health on every 15 dimensions. There was no sta-
tistically significant impairment on any of the dimensions compared 
to the general population (Figure 1). The nonparametric tests con-
firmed the statistically significant differences in the total 15D score 
0.956 (0.690-1.000) vs 0.914 (0.780-0.960) and in the dimensions 
of mobility 1.000 (0.710-1.000) vs 0.932 (0.670-0.990), usual ac-
tivities 1.000 (0.720-1.000) vs 0.918 (0.620-0.970) and eating 1.000 
(1.000-1.000) vs 0.998 (0.950-1.000), P < .001 for all comparisons, 
between the insulinoma patients and the general population.
3.2 | Determinants of the HRQoL in 
insulinoma patients
Among the patients with a previously treated insulinoma, younger 
age at the time of survey was associated with a better total 15D 
score (r = −0.414, P = .010), as well as with better scores on the 
dimensions of breathing (r = −0.409, P = .011), and discomfort 






(n = 28) Significance
n/median %/min–max n/median %/min–max n/median %/min–max
Median age, years 64.1 30.9-85.4 72.0 39.1-94.1
Median age at diagnosis, years 46.4 20.8-75.9 45.6 26.8-83.8 57.2 29.3-79.9 0.462
Median time since diagnosis, years 13.9 6.9-34.4 12.5 7.0-30.4
Gender (% of all)
Female 28 74 10 77 17 61 0.516
Male 10 26 3 23 11 39
Type of surgery (% of all)
Surgery with a curative aim 38 100 13 100 20 71 0.001*
Palliative surgery 0 0 0 0 2 7
No surgery 0 0 0 0 6 21
Surgical method (% of surgically treated)
Tumour enucleation 16 42 8 62 7 32 0.400
Distal pancreatic resection 16 42 5 38 12 55
Pancreaticoduodenectomy 6 16 0 0 3 14
Period of surgery (% of surgically treated)
1980s 4 11 1 8 8 36 0.092
1990s 9 24 4 31 6 27
2000s 25 66 8 62 8 36
Major surgical complicationsa  (% of surgically 
treated)
7 18 3 23 8 36 0.275
Metastasized disease (% of all) 2 5 0 0 7 25 0.026*
Note: Comparison between the participants of the HRQoL survey, the nonparticipants and the deceased patients. The characteristics were compared 
using the Mann-Whitney U test for continuous variables and the Fisher exact test for categorical variables.
aThe number of patients with major surgical complications (grades III-V of the Clavien-Dindo classification18,19). 
*Indicates a statistically significant difference (P < .05) between the three groups. Comparison between the participants and the nonparticipants did 
not show statistically significant differences in any of these characteristics. 
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and symptoms (r = −0.327, P = .045). Age at diagnosis, time since 
diagnosis, time since surgery or diagnostic delay (from the first 
symptoms up to the clinical diagnosis) had no statistically signifi-
cant correlation with the total 15D score (r = −0.246, P = .137; 
r = −0.131, P = .432; r = −0.148, P = .375 and r = −0.123, P = .468, 
respectively). BMI correlated negatively with scores on the dimen-
sions of moving (r = −0.343, P = .038) and breathing (r = −0.366, 
P = .026), but not with the total 15D score. Both the number of 
chronic diseases and the number of medications reported in the 
health questionnaire negatively correlated with the total 15D 
score (r = −0.550, P < .001; r = −0.573, P < .001, respectively), as 
well as with HRQoL on the dimensions of moving, seeing, breath-
ing, mental function, discomfort and symptoms, depression and 
vitality.
There was no significant difference in the mean 15D scores 
between the patients treated with pancreaticoduodenectomy 
(0.973 ± 0.033), tumour enucleation (0.932 ± 0.073) and partial 
pancreatic resection (0.913 ± 0.077, P = .092), nor between the 
patients with or without major surgical complications, classified as 
grades III-V of the Clavien-Dindo classification18,19 (0.927 ± 0.075 vs 
0.931 ± 0.072, P = .685). Likewise, no statistically significant differ-
ence was found in the total 15D scores between the patients requir-
ing pancreatic enzyme supplementation and those not using enzyme 
supplementation (mean 15D score 0.864 ± 0.152 vs 0.936 ± 0.062, 
P = .405). Among the insulinoma patients, there was no significant 
difference in the total 15D score by gender, cohabiting status or 
follow-up status (ie whether the follow-up of the insulinoma still 
continued or not). A higher level of education was associated with 
a better total 15D score (0.950 ± 0.054 vs 0.844 ± 0.081, P < .001), 
and better scores in breathing (0.961 ± 0.103 vs 0.741 ± 0.114, 
P = .002), discomfort and symptoms (0.865 ± 0.170 vs 0.631 ± 0.255, 
P = .027) and vitality (0.956 ± 0.092 vs 0.769 ± 0.235, P = .024). 
In the patients with hypertension (n = 18), the total 15D score was 
lower (0.898 ± 0.088) than in the patients without hypertension 
(0.959 ± 0.036, P = .017), and statistically significant impairment 
was detected on the dimensions of breathing (0.849 ± 0.156 vs 
0.985 ± 0.068, P = .017), discomfort and symptoms (0.740 ± 0.235 
vs 0.896 ± 0.146, P = .048) and depression (0.869 ± 0.147 vs 
0.977 ± 0.072, P = .033). Two of the study participants had a met-
astatic insulinoma and were followed up after surgical treatment 
performed with a curative aim several years before the survey. The 
mean total 15D score of the participants with a metastatic insuli-
noma was 0.895, and the patients reported impairment on several 
dimensions of the HRQoL.
4  | DISCUSSION
In the present study, the long-term overall HRQoL of insulinoma pa-
tients was slightly better than the HRQoL of the age- and gender-
adjusted sample of the general population. Insulinoma patients were 
doing better with regard to mobility, usual activities and eating and 
were not inferior to the controls on any dimension of the HRQoL. 
However, among the insulinoma patients, older age, a lower educa-
tional level and a larger number of chronic diseases and medications 
were associated with impaired HRQoL.
The insulinomas were benign and completely cured by the sur-
gery in 95% of the HRQoL survey respondents, which may explain 
the good self-reported HRQoL of insulinoma patients in this study. 
The reason for the better HRQoL of insulinoma patients compared 
to the general population in this study remains unclear. Our hypoth-
esis is that being cured of a potentially life-threatening disease may 
have a positive influence on the subjective quality of life of persons 
with a previous insulinoma in the long term. Similarly to our find-
ings, patients with a curatively treated NEN (n = 83) had a HRQoL 
similar to or better than the general population, in a previous study 
of 663 NEN patients.20 In another study of 217 surgically cured, re-
currence-free patients with a pancreatic or periampullary neoplasm, 
including 68 pancreatic NENs (panNEN), the QoL outcomes were 
TA B L E  2   Demographic data and self-reported chronic diseases 
of the 38 insulinoma patients participating in the HRQoL survey
n %
Marital status





Lower education 7 18
High school or above 31 82
Follow-up for insulinoma
Primary healthcare 3 8
Regional hospital 3 8
University hospital 2 5
No follow-up 29 76
Data missing 1 3
Chronic diseases
Hypertension 18 47






Other psychiatric disorder 1 3
Heart failure 1 3
Stroke 1 3
Other chronic diseasesb  8 21
aIncluding one patient with suspected postoperative secondary 
diabetes and three patients with type 2 diabetes. 
bOther chronic diseases included other cardiovascular diseases (n = 3), 
gastroesophageal reflux disease (n = 2), osteoporosis (n = 2), anaemia, 
goitre, pain syndrome and diverticulosis (n = 1 each). 
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comparable to the general population, and the incidence of clinically 
significant anxiety and depression was low after a median of 53.3 
(7.6-214.8) months following the surgery.21 In subsequent analy-
ses, distal pancreatectomy was an independent predictor of poorer 
HRQoL and increased anxiety and depression, compared to patients 
treated with pancreaticoduodenectomy.21 In our study, no signifi-
cant difference on HRQoL was found between patients treated with 
different surgical methods, but the statistical power was limited, as 
only 38 persons with a previously surgically treated insulinoma par-
ticipated in the HRQoL survey.
The median weight and BMI of insulinoma patients at the time 
of survey were significantly lower than at diagnosis, a median of 
13.9 years earlier. As weight loss and a lower BMI have been shown 
to be associated with improved HRQoL,22 it is possible that the fa-
vourable postoperative weight development of insulinoma patients 
may have contributed to the good overall and physical HRQoL in the 
long term. Among insulinoma patients, there was a negative cor-
relation between BMI and scores on the dimensions of moving and 
breathing. The confounding effect of a possible difference in weight 
between the patients and the controls on HRQoL, however, could 
not be assessed, as we had no data on the weight or BMI of the 
controls.
Significantly worse HRQoL scores (especially regarding physical 
functioning, physical role limitation, general health and vitality) have 
been reported in patients with a current, not cured NEN compared 
to the general population.20,23,24 These studies, however, have not 
specifically addressed insulinoma or panNEN patients. In our study, 
only two participants had a metastatic insulinoma, and both of them 
reported impairment on several dimensions of the HRQoL. Among 
the deceased patients of the insulinoma cohort, the prevalence of 
metastatic disease was significantly higher (25%) than in the partic-
ipants of the HRQoL survey, reflecting the poor survival of patients 
with a metastatic insulinoma. It is not possible to draw conclusions 
regarding the impact of malignant insulinomas on HRQoL in the 
present study, due to the paucity of malignant cases in the long-term 
survey.
In line with previous studies, age at the time of survey correlated 
negatively with HRQoL in the present study, especially regarding 
physical health (dimensions of breathing and discomfort and symp-
toms).20,23,24 Similar to some previous studies on NETs,20,23 we 
found no clear relationship between HRQoL and time after the insu-
linoma diagnosis. In our study, the minimum time since diagnosis was 
relatively long, 6.9 years. We found no correlation between HRQoL 
and the gender or the cohabiting status of the patients. Similar to 
our findings, these factors have been unrelated to the HRQoL in a 
previous study on patients with a NET.24
The major strengths of this study are the nationwide data and 
the high response rate of a rare patient group, with no HRQoL data 
reported previously. The survey participants were similar to the 
nonparticipants regarding demographic and insulinoma-specific fea-
tures. Therefore, the results are likely to represent well the long-
term HRQoL of typical insulinoma patients. The HRQoL in this study 
was assessed with the generic 15D instrument, with a good reliabil-
ity, validity and sensitivity,11,14 as well as age- and gender-adjusted 
reference values from a large, representative sample of the Finnish 
general population.10 The 15D has previously proved to be a sensi-
tive instrument for investigating the HRQoL in other endocrine tu-
mour diseases, such as small intestine NENs,8 thyroid carcinomas,25 
pituitary adenomas26,27 and primary hyperparathyroidism.28 The 
use of validated disease-specific tools in assessing the HRQoL of pa-
tients with a GEP-NET has been recommended in recent reviews.5,6 
To date, two GEP-NET-specific HRQoL questionnaires have been 
introduced: the QLQ-GINET21 applied together with the European 
Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC QLQ-C30),29,30 and the Norfolk 
QOL-NET.31 Neither instrument, however, is fully applicable to pa-
tients with an insulinoma, as the questionnaires do not address the 
specific symptoms of insulinoma patients (eg fear of collapses and 
other hypoglycaemic symptoms).29-31
There are also some limitations to this study. Due to the rarity 
of the disease, the sample size is relatively small. With the small 
number of malignant cases and only one case associated with the 
F I G U R E  1   The mean 15D HRQoL 
profiles and the mean total 15D score 
of persons with a previously treated 
insulinoma (n = 38) and an age- and 
gender-matched cohort of the Finnish 
general population (n = 4692).10 * 
indicates a statistically significant 
difference (P < .05) between the groups
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MEN1 syndrome, we were not able to evaluate comprehensively the 
HRQoL of patients with a metastatic insulinoma or with a hereditary 
tumour syndrome. Likewise, the effect of the different pharmacolog-
ical treatment options of insulinoma, or the effect of complications 
such as postoperative secondary diabetes or exocrine pancreatic in-
sufficiency, on HRQoL could not be definitively assessed. A larger 
study population might be needed to detect possible differences 
in the HRQoL of insulinoma patients treated with different surgi-
cal methods. We could not assess the efficacy of the treatment on 
patients’ HRQoL, as we did not measure the HRQoL before surgery. 
In addition, the confounding effect of other factors, for example a 
possible difference in weight between the patients and the controls, 
on HRQoL could not be ruled out. Finally, as the study population 
consisted of Finnish subjects only, the results might not be directly 
generalizable to other populations.
In conclusion, the long-term HRQoL of patients with a previously 
treated insulinoma in Finland was slightly better than that of the 
general population. No significant difference was found in the long-
term HRQoL between the surgical methods used. In the long-term 
follow-up of patients with a previously treated insulinoma, the pre-
vention and treatment of comorbidities is essential, as the number 
of chronic diseases and medications are the most important deter-
minants of HRQoL in insulinoma patients.
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